Cuprina Holdings (Cayman) Limited Announces Closing of Initial Public Offering

Winston & Strawn is serving as underwriters counsel to R.F. Lafferty in connection with Cuprina Holdings, a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds as well as cosmeceuticals for the health and beauty sector, in its announced closing of $12,000,000 initial public offering. The Offering consists of 3,000,000 ordinary shares at a public offering price of $4 per share, for total gross proceeds of $12,000,000, before deducting underwriting discounts and offering expenses.

 

The Company intends to use net proceeds from the Offering for expansion into new markets, R&D activities to expand its product portfolio, research and development activities, building brand awareness, investment in equipment and infrastructure, and working capital and general corporate purposes.